Terms: = Leukemia AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Prognosis
137 results:
1. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
Stilgenbauer S; Tausch E; Roberts AW; Davids MS; Eichhorst B; Hallek M; Hillmen P; Schneider C; Schetelig J; Böttcher S; Kater AP; Jiang Y; Boyer M; Popovic R; Ghanim MT; Moran M; Sinai WJ; Wang X; Mukherjee N; Chyla B; Wierda WG; Seymour JF
Blood Adv; 2024 Apr; 8(8):1992-2004. PubMed ID: 38290108
[TBL] [Abstract] [Full Text] [Related]
2. Tyrosine Kinase Inhibitor Therapies in Chronic Myeloid leukemia: Effects on Clinical Characteristics and Triglyceride-to-High Density Lipoprotein Cholesterol Ratio.
Erkek ET; Isik AC; Ipek Y; Kul AN
Niger J Clin Pract; 2023 Jun; 26(6):802-809. PubMed ID: 37470656
[TBL] [Abstract] [Full Text] [Related]
3. Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.
Jin H; Zhang Y; Yu S; Du X; Xu N; Shao R; Lin D; Chen Y; Xiao J; Sun Z; Deng L; Liang X; Zhang H; Guo Z; Dai M; Shi P; Huang F; Fan Z; Yin Z; Xuan L; Lin R; Jiang X; Yu G; Liu Q
J Hematol Oncol; 2023 Apr; 16(1):42. PubMed ID: 37120593
[TBL] [Abstract] [Full Text] [Related]
4. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
Jonas BA; Hou JZ; Roboz GJ; Alvares CL; Jeyakumar D; Edwards JR; Erba HP; Kelly RJ; Röllig C; Fiedler W; Brackman D; Siddani SR; Chyla B; Hilger-Rolfe J; Watts JM
Hematol Oncol; 2023 Oct; 41(4):743-752. PubMed ID: 37086447
[TBL] [Abstract] [Full Text] [Related]
5. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Duong VH; Ruppert AS; Mims AS; Borate U; Stein EM; Baer MR; Stock W; Kovacsovics T; Blum W; Arellano ML; Schiller GJ; Olin RL; Foran JM; Litzow MR; Lin TL; Patel PA; Foster MC; Redner RL; Al-Mansour Z; Cogle CR; Swords RT; Collins RH; Vergilio JA; Heerema NA; Rosenberg L; Yocum AO; Marcus S; Chen T; Druggan F; Stefanos M; Gana TJ; Shoben AB; Druker BJ; Burd A; Byrd JC; Levine RL; Boyiadzis MM
Cancer; 2023 Aug; 129(15):2308-2320. PubMed ID: 37078412
[TBL] [Abstract] [Full Text] [Related]
6. Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population-based study in France.
Atsou KM; Rachet B; Cornet E; Chretien ML; Rossi C; Remontet L; Roche L; Giorgi R; Gauthier S; Girard S; Böckle J; Wasse SK; Rachou H; Bouzid L; Poncet JM; Orazio S; Monnereau A; Troussard X; Mounier M; Maynadie M
Cancer Med; 2023 Apr; 12(7):8911-8923. PubMed ID: 36710405
[TBL] [Abstract] [Full Text] [Related]
7. [Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation].
Chen X; Liu ZY; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):542-549. PubMed ID: 36709130
[No Abstract] [Full Text] [Related]
8. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
[TBL] [Abstract] [Full Text] [Related]
9. Association of Genetic Ancestry With the Molecular Subtypes and prognosis of Childhood Acute Lymphoblastic leukemia.
Lee SHR; Antillon-Klussmann F; Pei D; Yang W; Roberts KG; Li Z; Devidas M; Yang W; Najera C; Lin HP; Tan AM; Ariffin H; Cheng C; Evans WE; Hunger SP; Jeha S; Mullighan CG; Loh ML; Yeoh AEJ; Pui CH; Yang JJ
JAMA Oncol; 2022 Mar; 8(3):354-363. PubMed ID: 35084434
[TBL] [Abstract] [Full Text] [Related]
10. Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report.
Vo K; Guan T; Banerjee R; Lo M; Young R; Shah N
J Oncol Pharm Pract; 2022 Jul; 28(5):1244-1248. PubMed ID: 35084252
[TBL] [Abstract] [Full Text] [Related]
11. [The Effect of Immunized Platelet Transfusion Refractoriness on Allo-HSCT Patients with Malignant Hematological Diseases].
Zuo YL; Zhai JP; Li Y; Jiang M; Cui QY; Tang XW; Zhao YM; Zhang JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1923-1928. PubMed ID: 34893135
[TBL] [Abstract] [Full Text] [Related]
12. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
13. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Davids MS; Rogers KA; Tyekucheva S; Wang Z; Pazienza S; Renner SK; Montegaard J; Ihuoma U; Lehmberg TZ; Parry EM; Wu CJ; Jacobson CA; Fisher DC; Thompson PA; Brown JR
Blood; 2022 Feb; 139(5):686-689. PubMed ID: 34788401
[TBL] [Abstract] [Full Text] [Related]
14. Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis.
Visram A; Vachon C; Baughn LB; Larson D; Smadbeck J; Dispenzieri A; Kapoor P; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Gonsalves W; Warsame R; Muchtar E; Leung N; Kyle RA; Rajkumar SV; Kumar S
Leukemia; 2022 Apr; 36(4):1058-1065. PubMed ID: 34764424
[TBL] [Abstract] [Full Text] [Related]
15. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Kim K; Maiti A; Loghavi S; Pourebrahim R; Kadia TM; Rausch CR; Furudate K; Daver NG; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Tang G; Ravandi F; Kantarjian HM; DiNardo CD; Konopleva MY
Cancer; 2021 Oct; 127(20):3772-3781. PubMed ID: 34255353
[TBL] [Abstract] [Full Text] [Related]
16. PEP-CoV protocol: a PEP flute-self-care randomised controlled trial to prevent respiratory deterioration and hospitalisation in early COVID-19.
Mollerup A; Larsen SC; Bennetzen AS; Henriksen M; Simonsen MK; Weis N; Kofod LM; Heitmann BL
BMJ Open; 2021 Jun; 11(6):e050582. PubMed ID: 34193503
[TBL] [Abstract] [Full Text] [Related]
17. Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
Choi EJ; Lee JH; Kim H; Choi Y; Lee WS; Lee SM; Park JH; Park HS; Lee JH; Lee KH;
Int J Hematol; 2021 Jun; 113(6):851-860. PubMed ID: 33655416
[TBL] [Abstract] [Full Text] [Related]
18. Mass Spectrometry: A Powerful Method for Monitoring Various Type of leukemia, Especially MALDI-TOF in leukemia's Proteomics Studies Review.
Fasih Ramandi N; Faranoush M; Ghassempour A; Aboul-Enein HY
Crit Rev Anal Chem; 2022; 52(6):1259-1286. PubMed ID: 33499652
[TBL] [Abstract] [Full Text] [Related]
19. [Expressing of linc-223 and miR-125a in Patients with Acute leukemia and Its Clinical Significance].
Liu AF; Chen YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1819-1825. PubMed ID: 33283704
[TBL] [Abstract] [Full Text] [Related]
20. Outcome and Prognostic Features in Pediatric Acute Megakaryoblastic leukemia Without Down Syndrome: A Retrospective Study in China.
Wang Y; Lu A; Jia Y; Zuo Y; Zhang L
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e301-e308. PubMed ID: 33257285
[TBL] [Abstract] [Full Text] [Related]
[Next]
